GRL-0617是一種藥物，是最早被發現可作為木瓜蛋白酶樣蛋白酶（PLP）的選擇性小分子抑制劑的化合物之一，PLP可在某些致病病毒（包括冠狀病毒SARS-CoV-2）中發現。它已被證明可以在體外抑制病毒複製。[1][2][3][4]
- ^ Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. November 2020, 587 (7835): 657–662. Bibcode:2020Natur.587..657S. PMC 7116779
. PMID 32726803. doi:10.1038/s41586-020-2601-5.
- ^ Hajbabaie R, Harper MT, Rahman T. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease (PDF). Molecules. February 2021, 26 (4): 1134 [2022-12-12]. PMC 7924369 . PMID 33672721. doi:10.3390/molecules26041134 . （原始內容存檔 (PDF)於2022-12-12）.
- ^ Lim CT, Tan KW, Wu M, Ulferts R, Armstrong LA, Ozono E, et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease. The Biochemical Journal. July 2021, 478 (13): 2517–2531. PMC 8286840 . PMID 34198325. doi:10.1042/BCJ20210244.
- ^ Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y, et al. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharmaceutica Sinica. B. July 2021. PMC 8260826 . PMID 34249607. doi:10.1016/j.apsb.2021.06.016.
